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1. Introduction 
Bowman-Birk inhibitor (BBI) of soybean is a 
double-headed inhibitor with independent activity 
against both trypsin (EC 3.4.21.4) and chymotrypsin 
(EC 3.4.21.1) [ 1 ]. The Lys 16-Ser 17 and Leu 43-Ser 44 
bonds were assigned to be the anti-tryptic and anti- 
chymotryptic sites, respectively. Each reactive site is 
located within a disulfide loop of 9 residues [2]. Cyclic 
I 
nonapeptides, X-Cys-Thr-Lys-Ser-Asn-Pro-  
Pro-Gln-Cys-Y (I a: X=Ac, Y=NH2; I b: X=H, Y=OH), 
corresponding to residues 14-22 in the sequence of 
BBI by solid-phase method and showed their anti- 
tryptic activities. 
We report how the synthesis by conventional 
method and the inhibitory activity of cyclic nona- 
I 
peptides, X-Cys-Ala-Leu-Ser-Tyr-Pro-Ala-  
Gln-~ys-Y (IIa: X=Ac, Y=NH2; lib: X=H, Y=OH), 
which corresponds tothe sequence of 41-49 of BBI in- 
volving anti-chymotryptic site. We also examined the 
effect of replacement at P2, PI and P~ residues of I a and 
II a on the inhibitory properties toward trypsin, chymo- 
trypsin and subtilisin BPN' (EC 3.4.21.1 4). The anti- 
chymotryptic site peptides inhibited both chymo- 
trypsin and subtilisin, whereas the natural inhibitor 
was ineffective to subtilisin. 
Residues inpeptides and the corresponding subsites in
enzyme are numbered according toSehechter and Berger 
[5]. Abbreviations according toIUPAC-IUB commission 
(1972), J. Biol. Chem. 247, 977-983, are used throughout. 
pNA, p-nitroanilide; Cys(MeOBzl), S-4-methoxybenzyl- 
cysteine; Cys(Cam), S-carboxamidomethylcysteine. Ami o 
acids other than Gly and D-Lys are of L-eonfguration. 
2. Materials and methods 
ct-Chymotrypsin (3 X crystallized), trypsin 
(2 × crystallized) and subtilisin BPN' (Nagarse) were 
supplied by Worthington Biochemical Corp. (NJ), by 
Nutritional Biochemical Corp. (OH) and by Nagase 
Co. (Osaka), respectively. Natural BBI was prepared 
from soybeans following [6]. 
2.1. Synthesis o/'1I a and11 b
The protected nonapeptide (177 mg), Ac-Cys- 
(MeOBzl)-Ala-Leu-Ser(Bzl)-Tyr-Pro-Ala-Gln- 
Cys(MeOBzl)-NH2, prepared by condensing Ac-Cys- 
(MeOBzl)-Ala-Leu-N3 with H-Ser(Bzl)-Tyr- 
Pro-Ala-Gln-Cys(MeOBzl)-NH2 was de-blocked 
by HF in the presence of anisole, and the peptide 
obtained was oxidized with potassium ferricyanide to 
form disulfide linkage. The crude product desalted 
by Sephadex G-15 (50% acetic acid) was purified by 
Sephadex G.25 (2.8 × 166 cm) using 10% acetic acid 
as eluent; yield of IIa, 73 mg (54%). Dimer of II a 
(28 mg, 21%) was also gained by this procedure. 
II b was obtained from Boc-Cys(MeOBzl)-Ala- 
Leu-Ser(Bzl)-Tyr-Pro-Ala-Gln-Cys(MeOBzl)- 
OBzl (90 mg) in the same manner as above; yield of lib, 
20 mg (34%). Details of the synthesis will be reported 
elsewhere. 
2.2. Synthesis of  other peptides 
All the peptides including Ia, I b and several analogs 
of I a and II a were synthesized by conventional methods, 
to be reported elsewhere, and are summarized in
table 1. Reduced and carboxamidomethylated nalog 
of IIa, an open chain peptide (IId), was prepared from 
II a as for the preparation of I h [4]. 
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Table 1 
Synthetic peptides related to the nonapeptide sequences 
(14-22 and 41-49)  of BBI 
Structure 
Peptide 
Sequence (14-22) 
of BBI 
I a 
I b 
I c 
I d 
I e 
If 
Ig 
I h 
Sequence (41-49) 
of BBI 
II a 
IIb 
II c 
IId 
-Cys-Thr -Lys-Ser-Asn-Pro-Pro-G1n-Cys- 
~-Cys-Thr-Lys-Ser-Asn-Pro-Pro-Gln-~s-NH 2 
H-Cys -Thr -Lys-Ser -Asn-Pro-Pro-GIn-~s-OH 
Ac-Cys-Thr-D-Lys-Ser-Asn-Pro-Pro-Gln-~ys-NH 2 
AC -Cys-Thr -Arg-Ser -Asn-Pro-Pro-Gln-~ys-NH 2 
AC-Cys -Ala- Lys -Ser-Asn-Pro-Pro-Gln-~ys-NH 2 
Ac-Cys-Thr -Lys-Ala-Asn-Pro-Pro-G1n-~ys-NH 2 
Ac-~ys -Thr-Leu-Ser-Asn-Pro-Pro-Gln-~ys -NH 2 
cam ~am 
AC-~S -Thr-Lys-Ser -Ash-Pro-Pro-Gin -Cys-NH 2 
-~ys-Ala-Leu-Ser -Tyr-Pro-A1a-G1n-Cys- 
kc-~ys-A1a-Leu-Ser -Tyr -Pro-Ala-Gln-~ys-NH 2 
H-~ys-Ala-Leu-Ser -Tyr-PrO-AIa-GIn-~s-OH 
Ac-~ys-Ala-Tyr-Ser-Tyr -Pro-Ala-Gln-~ys-NH 2 
Ac-~-Ala-Leu-Ser-Tyr -Pro-A 1 a-Gln-~-Nll 2 
2.3. Enzyme assays and kinetic measurements 
Esterase activities of chymotrypsin and trypsin 
were determined spectrophotometrically at25°C with 
Ac-Tyr-OEt [7] and Tos-Arg-OMe [8] as sub- 
strates, respectively, p-Nitroanilides were employed 
to examine amidase activities at 410 nm; Bz-Arg-pNA 
for trypsin [9] and Boc-Gly-Ala-Leu-pNA 
(prepared in our laboratory; kcat/Km=970 M -1 .s -l , 
Km=0.62 raM, at pH 8.0) for subtilisin BPN'. The 
inhibition constants (Ki) were calculated from the 
initial rate of hydrolysis at various concentrations of 
the substrate by the methods in [10,11]. 
3. Results and discussion 
II a and II b inhibited chymotrypsin competitively, 
though the activities were about 104-times weaker 
than natural inhibitor (table 2). In contrast to the 
anti-tryptic site nonapeptides [4], dimer of II a showed 
similar inhibitory activity of that of II a. Replacement 
of Pt residue (Leu) by Tyr enhanced the potency of 
inhibition in accord with primary specificity of sub- 
strate. Interestingly the most potent inhibitor of 
chymotrypsin is Ig, an analog of anti-tryptic site 
peptide. Relatively high activity (Ki=290/aM) of the 
Table 2 
Competitive inhibition of chymotrypsin and subtilisin BPN' by 
several peptides and natural BBI 
Peptide 
K i 0~M) for chymottyps~n 
Ac-Tyr-OEt a 
K i 0~M) for subtifisin 
Boc -G ly -A la -Leu-pNA b 
I a no inhibition no inhibition 
Ig 5.7 2900 
II a 52 11 
l i  b 180 170 
II c 13 55 
II d 290 - 
Dimer of II a 45 170 
BBI 0.008 no inhibition 
a 0.05 M phosphate buffer (pH 7.0) containing 3% methanol at 25°C 
b 0.05 M phosphate buffer (pH 8.0) containing 16% N,N-dimethylformamide at 
25°C 
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open chain analog (IId) indicates that the loop struc- 
ture with a disulfide bond is not indispensable for the 
inhibitory property to chymotrypsin, but it may con- 
tribute to the conformational specificity [12] by 
positioning P4-P'2 residues of the inhibitor to the 
rigid optimum conformation for binding to the 
enzyme. 
Natural BBI has been known not to inhibit bacterial 
proteinase [13]. We confirmed it with subtilisin BPN' 
(table 2). All the peptides related to anti-tryptic site 
were ineffective for this enzyme xcept Ig, which 
showed very weak inhibition. However, the anti-chymo- 
tryptic site fragment, Ila, strongly inhibited subtilisin 
BPN' (Ki=l I/aM, table 2), indicating the broad 
specificity of this loop itself. This observation is inter- 
esting from both the evolutional nd the structural 
points of view on BBI molecule. The lack of strict 
specificity of these model inhibitors compared to 
natural BBI may be the results of either slightly 
different conformation or the lack of other contact 
regions uch as P4 amino acid residue in these peptides, 
or both. 
To gain further understanding the role of amino 
acid residues near anti-tryptic site of BBI, we tested 
the inhibitory activity of several analogs of I a on 
esterase and amidase activities of trypsin (table 3). 
Introduction of D-Lys into PI residue practically 
abolished the inhibitory activity. Replacement of Lys 
(Pt) residue by Arg did not affect he anti-tryptic 
potency. Replacements of two amino acid residues 
(Thr and Ser; adjacent to the reactive site) afforded 
different effects: alteration i  P2 caused ahigher 
increase in K i value than P~ (table 3). This can be 
explained by the insufficient contact of P2 side chain 
(methyl group) of I e with $2 subsite (Leu 99) of the 
enzyme. Replacing of the P1 residue (Lys) of I a by 
Leu abolished the anti-tryptic activity (Ig in table 3), 
but it converted the peptide into chymotrypsin 
inhibitor (table 2). This will provide a good support 
for the hypothesis of evolution of double-headed 
inhibitor [14]. Enzymatic mutation of PI residue has 
been achieved for Kunitz soybean trypsin inhibitor 
[15] and basic pancreatic trypsin inhibitor [16]. 
All of the peptides tested here was stable during 
the incubation period. Somatostatin having similar 
molecular size, possible reactive site (Lys-X), and 
cyclic structure with a disulfide bond did not inhibit 
trypsin but was hydrolyzed rapidly by the enzyme. 
C-Terminal undecapeptide of ovine prolactin, H -Leu-  
I . . . .  | 
Asn-Cys-Arg- I le- I le-Tyr-Asn-Asn-Asn-Cys-  
OH, did not inhibit trypsin and chymotrypsin [17]. 
Table 3 
Competitive inhibition of trypsin by several peptides and 
natural BBI 
Peptide 
K i (~M) for trypsin 
Tos-Arg-OMe Bz-Arg-pNA 
I a 0.75 0.76 
I b 3.6 3.9 
I e 860 850 
I d 0.90 1.3 
I e 16 16 
If 3.5 3.0 
lg no inhibition no inhibition 
I h - 100 
BBI 0.003 - 
0.05 M Tris buffer (pH 8.0 for Tos-Arg-OMe and pH 8.2 
for Bz-Arg-pNA) containing 0.01 M CaCI2 at 25°C 
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